# A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis

> **NCT01085097** · PHASE2 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 46 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** Laquinimod
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Prednisolone/Prednisone
- **DRUG:** Placebo
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT01085097
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09-01
- **Primary completion:** 2012-10-24
- **Final completion:** 2012-10-24
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2022-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01085097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01085097, "A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01085097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*